Lipomas and Liposarcomas

The invention provides methods of treatment of lipomas or liposarcomas. Lipoma types include, e.g., angiolipoma, angiolipoleiomyoma, neural fibrolipoma, chondroid lipoma, spindle-cell lipoma, pleomorphic lipoma, intradermal spindle cell lipoma, hibernoma, and superficial subcutaneous lipoma. Glycine and/or glycine analogs can be used to treat lipomas or liposarcomas at injectable concentrations of about 0.1, 0.2, 0.5, 0.75, 1.0, 2.0, 2.5, 5.0, 7.5, 10.0, or 15.0 mg/ml or more. Alternatively, glycine and/or glycine analogs can be used to treat lipomas or liposarcomas at concentrations of about 15.0, 10.0, 7.5, 5.0, 2.5, 2.0, 1.0, 0.75, 0.5, 0.2, 0.1 mg/ml or less or any range between 15 and 0.1 mg/ml. Glycine and glycine analogs can be present at a concentration of about 0.5 1, 2, 3, 4, 5, 10, 15% or more or any range between about 0.5% and about 15%. Neutral glycine can be present in a solution of water or any pharmaceutically acceptable carrier. Glycine and/or glycine analogs can be administered parenterally, e.g., percutaneously, subcutaneously, intravascularly (e.g., intravenously), intramuscularly, intraarterial, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneally, transtracheal, subcuticular, subcapsular, subarachnoid, intraspinal, intrasternal, or intrathecaly injection or infusion, or topically or orally (as described above).

Glycine and/or glycine analogs can also be administered by direct injection into the lipoma or liposarcoma or injection into the area surrounding the lipoma or liposarcoma. Several divided dosages of glycine and/or glycine analogs, as well as staggered dosages, can be administered or the dose can be continuously infused, or can be a bolus injection or infusion. Furthermore, the dosages can be proportionally increased or decreased as indicated by the exigencies of the therapeutic or prophylactic situation. Treatment of a lipoma or liposarcoma means the reduction or elimination of the lipoma or liposarcoma.

Administration of glycine and/or glycine analogs can occur four, three, two, or one times a day. Administration can also occur four, three, two, or one time a week or three, two, or one time a month. Administration of can continue until the lipoma or liposarcoma shrinks 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% (by weight or volume), or until the lipoma or liposarcoma is eliminated.

Treatment of Lipoma or Liposarcoma in an Animal

Using known techniques (e.g., diagnosis by a medical professional), an animal (e.g., a human, dog, cat, horse, etc.) in need of treatment for lipoma or liposarcoma can be identified. A therapeutically effective amount of glycine and/or glycine analogs can be administered parenterally, e.g., percutaneously, subcutaneously, intravascularly (e.g., intravenously), intramuscularly, intraperitoneally or intrathecaly injection, by infusion techniques, orally, or by any other suitable administration method.

At intervals during the treatment regimen, the animal is monitored for signs and symptoms of lipoma or liposarcoma. After the treatment period has concluded, again using known techniques, the animal is found to have decreased signs and symptoms of lipoma or liposarcoma and/or to be no longer in need for treatment or reduced treatment for lipoma or liposarcoma. The lipoma or liposarcoma size is reduced by about 5. 10, 25, 50, 75, or 100% or any range between about 5% and 100%.